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Statement of Translational Relevance
High-grade serous ovarian carcinoma (HGSOC) is the fifth leading cause of cancer death in the
United States and Canada. The majority of HGSOC are diagnosed as late-stage, high-grade
serous ovarian carcinomas, for which prognosis is generally poor and few targeted therapies
exist. Significant research effort has suggested several molecularly distinct subtypes of
HGSOC, yet no consensus in the field exists and computational methods to analyze highdimensional gene expression datasets differ across studies. Although subtypes have been
shown to differ in overall survival, the lack of agreement on molecular subtype definition has
been cited as a barrier to their investigation through clinical trial. In the present study, we
perform an analysis of a large compendium of HGSOC transcriptomes in order to evaluate the
concordance of computational methods and address the emerging consensus in the field. We
develop a subtype classifier that represents the consensus of HGSOC subtypes, and show that
many tumors are of intermediate or mixed subtype based on currently defined subtypes. These
findings improve our understanding of the molecular basis of high-grade serous carcinoma, an
important step in defining the underlying biology and identifying therapeutic targets of HGSOC.
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Abstract
Purpose: The majority of ovarian carcinomas are of high-grade serous histology, which is
associated with poor prognosis. Surgery and chemotherapy are the mainstay of treatment, and
molecular characterization is necessary to lead the way to targeted therapeutic options. To this
end, various computational methods for gene expression-based subtyping of high-grade serous
ovarian carcinoma (HGSOC) have been proposed, but their overlap and robustness remain
unknown.
Experimental Design: We assess three major subtype classifiers by meta-analysis of publicly
available expression data, and assess statistical criteria of subtype robustness and classifier
concordance. We develop a consensus classifier that represents the subtype classifications of
tumors based on the consensus of multiple methods, and outputs a confidence score. Using our
compendium of expression data, we examine the possibility that a subset of tumors are
unclassifiable based on currently proposed subtypes.
Results: HGSOC subtyping classifiers exhibit moderate pairwise concordance across our data
compendium (58.9%-70.9%, p < 10-5) and are associated with overall survival in a metaanalysis across datasets (p < 10-5). Current subtypes do not meet statistical criteria for
robustness to re-clustering across multiple datasets (Prediction Strength < 0.6). A new subtype
classifier is trained on concordantly classified samples to yield a consensus classification of
patient tumors that correlates with patient age, survival, tumor purity, and lymphocyte infiltration.
Conclusion: A new consensus ovarian subtype classifier represents the consensus of
methods, and demonstrates the importance of classification approaches for cancer that do not
require all tumors to be assigned to a distinct subtype.
.
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Introduction
Ovarian carcinoma is a genomically complex disease, for which the accurate characterization of
molecular subtypes is difficult but is anticipated to improve treatment and clinical outcome(1).
Substantial effort has been devoted to characterize molecularly distinct subtypes of high-grade
serous ovarian carcinoma (HGSOC) (Table 1). Initial large-scale efforts to classify HGSOC of
the ovary did not reveal any reproducible subtypes(2). Tothill et al(3) reported four distinct
HGSOC subtypes: (i) an immunoreactive expression subtype associated with infiltration of
immune cells, (ii) a low stromal expression subtype with high levels of circulating CA125, (iii) a
poor prognosis subtype displaying strong stromal response, correlating with extensive
desmoplasia, and (iv) a mesenchymal subtype with high expression of N/P-cadherins. The
Cancer Genome Atlas (TCGA) project also identified four subtypes characterized by (i)
chemokine expression in the immunoreactive subtype, (ii) proliferation marker expression in the
proliferative subtype, (iii) ovarian tumor marker expression in the differentiated subtype, and (iv)
expression of markers suggestive of increased stromal components in the mesenchymal
subtype, but did not report

differences in patient survival(4). Further experimental

characterization revealed an increased number of samples with infiltrating T lymphocytes for the
immunoreactive subtype, whereas desmoplasia, associated with infiltrating stromal cells, was
found more often for the mesenchymal subtype(5). Konecny et al.(6), independently evaluated
the TCGA subtypes and also reported the presence of the four transcriptional subtypes using a
de novo clustering and classification method.

However, robustness and clinical relevance of these subtypes remain controversial(7). The
previous subtyping efforts have assessed prognostic significance in different patient cohorts,
and have taken different approaches to validate these subtypes in independent datasets. A
4

recent review of HGSOC subtyping schemes highlighted the difficulty of comparing results of
studies that used different subtyping algorithms, and that better general agreement on how
molecular subtypes are defined would allow more widespread use of expression data in clinical
trial design.(1)

Assessing the generalizability of subtyping algorithms is challenging as true subtype
classifications remain unknown. This challenge is evident in the lack of published validation of
the proposed HGSOC subtypes. Subsequent efforts have performed de novo clustering of new
datasets and noted similarity in the clusters identified, but they have not reported quantitative
measures such as classification accuracy or rate of concordance with previously published
algorithms(8). In this article, we address these limitations by re-implementing three major
subtyping methods(3,5,9) and assess between-classifier concordance and across-dataset
robustness in a widely used database containing 1,770 HGSOC tumors(10), whose curation
and data consistency has been independently validated(11). We show that each pair of subtype
classifiers are significantly concordant, and are virtually identical for tumors classified with high
certainty. However, the subtypes do not meet established standards of robustness to reclustering(12) and only approximately one-third of tumors are classified concordantly by all three
subtype classifiers. Using this core set of tumors concordantly classified by each method, we
develop consensusOV, a consensus classifier that has high concordance with the three
classifiers, therefore providing a standardized classification scheme for clinical applications.

Materials and Methods
Datasets
Analysis was carried out on datasets from the curatedOvarianData compendium; details of
curation and of grading systems used by individual studies are described elsewhere (10).
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Datasets were additionally processed using the MetaGxOvarian package(13) (Supplementary
Information).

Analysis

was

restricted

to

datasets

featuring

microarray-based

whole-

transcriptome studies of at least 40 patients with late stage, high-grade, primary tumors of
serous histology. This resulted in 15 microarray studies, providing data for 1,774 patients (Table
2). Duplicated samples identified by the doppelgangR package were removed(14). Survival
analysis was performed for 13 of these datasets, which included 1,581 patients with annotated
time to death or last time of follow-up.

Implementation of Subtype Classifiers
Subtype classifiers were re-implemented in R(15) using original data as described by
Konecny(6), Verhaak(5), and Helland(9). These classifiers are based on nearest-centroids(6),
subtype-specific

single-sample

GSEA(5),

and

subtype-specific

linear

coefficients(9),

respectively. Implementations were validated by reproducing a result from each of the original
publications (Supplemental File, Section ‘Reproduction of Published HGSOC Subtype
Classifiers’).

Survival Analysis
Subtype calls from all included datasets were combined to generate a single Kaplan-Meier plot
for each subtyping algorithm (stratified by subtype). Hazard ratios for overall survival between
subtypes was estimated by Cox proportional hazards, and statistical significance was assessed
by log-rank test using the survcomp R package(16). Hazard ratios were calculated using the
lowest-risk subtype as the baseline group, and stratification by dataset was performed for
hazard ratios and significance testing.

Prediction Strength
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Prediction Strength(12) is defined as a measure of the similarity between pairwise comemberships of a validation dataset from class labels assigned by (1) a clustering algorithm
and (2) a classification algorithm trained on a training dataset (Supplementary Figure 1). The
quantity is an established measure of cluster robustness with the following interpretation: a
value of 0 or below indicates poor concordance, and a value of 1 indicates perfect concordance
between models specified from training and validation data. Tibshirani and Walther(12), and
subsequent applications of Prediction Strength(17), have considered a value of at least 0.8 to
be an evidence of robust clusters. Prediction Strength was computed as implemented in the
genefu Bioconductor package(18).

The tumors in each dataset were clustered de novo using our reproduced implementations of
the algorithms of Konecny, TCGA/Verhaak, and Tothill (Supplemental File, Section
‘Reproduction of Subtype Clustering Methods’). Each dataset was also classified using
implementation of the originally published subtype classifiers. This produced two sets of subtype
labels for each sample in each validation dataset; these labels were used to compute Prediction
Strength.

Concordance Analysis
For each pair of classifiers, subtypes were mapped based on the observed concordance
suggested in the original studies: Subtype C2 from Tothill corresponding to Immunoreactive in
TCGA/Verhaak and C1_Immunoreactive-like in Konecny; C4 corresponding to Differentiated
and C2_Differentiated-like; C5 corresponding to Proliferative and C3_Proliferative-like; and C1
corresponding to Mesenchymal and C4_Mesenchymal-like. Statistical significance of pairwise
concordance was assessed by Pearson’s Chi-squared test, and Cramer’s V was assessed to
evaluate the strength of concordance. Two-way concordance was defined as the proportion of
patients that were classified as the same mapped subtype across methods. Similarly, overall
7

three-way concordance was defined as the proportion of tumors sharing the same mapped
subtype across all three classifiers. Subtype-specific three-way concordance was defined as the
number of tumors concordantly classified as that subtype by all three classifiers, divided by the
number of tumors classified to that subtype by at least one method.

Filtering tumors by classification margin
Each subtype classifier outputs for each patient a real-valued score for each subtype. Marginally
classifiable tumors were identified based on the difference between the top two subtype scores,
denoted as the ‘margin’ value. Thus, a higher margin indicates a more confident classification.
For each pair of subtype classifiers, classification concordance was assessed on both the full
dataset and considering only patients classified with margins above a user-defined cutoff.

Building a consensus classifier
The consensusOV classifier was implemented using a Random Forest classifier trained on
concordantly-subtyped tumors across multiple datasets. The Random Forest method has
previously been used for building a multi-class consensus classifier to resolve inconsistencies
among published colorectal cancer subtyping schemes(19). In order to avoid normalizing
expression values across datasets, binary gene pair vectors were used as feature space, as
recently applied for breast cancer subtyping(20,21). To address differences in gene expression
scales due to different experimental protocols, consensusOV first standardizes genes in each
dataset to the same mean and variance, and computes binary gene pairs from standardized
expression values. Since the feature size of this classifier increases quadratically with respect to
the size of the original gene set, we used the smallest gene set of the original subtype
classifiers (the gene set of Verhaak et al.(5)), which contains 100 gene symbols. The
consensusOV classifier outputs the subtype classification and a real-valued margin score to
discriminate between patients that are of well-defined or indeterminate subtype. Similarly to
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previously published subtype classifiers, a higher margin score indicates higher confidence of
classification.

Leave-one-dataset-out cross-validation
Performance of the consensus classifier for identifying concordantly classified subtypes was
assessed using leave-one-dataset-out cross-validation(22). Concordant subtypes were
identified to train the Random Forest classifier using 14 of the 15 datasets, and subtype
predictions were tested in the remaining left-out dataset. This process was repeated for all 15
datasets. While predicting the samples in any given dataset, the training set was subsetted to
contain only the concordant subtypes in other datasets.

Correlation analysis with Histopathology and Tumor Purity
Subtype calls from the Consensus Classifier were analysed for correlation with histopathology
and tumor purity in the TCGA dataset. In order to best represent the most confident subtype
calls, a default cutoff was used to include only the 25% of patients with the largest classification
margins. Available histopathology variables included lymphocyte, monocyte, and neutrophil
infiltration. Tumor purity was assessed using the ABSOLUTE algorithm(23), which estimates
purity and ploidy from copy number and SNP allele frequency from SNP genotyping arrays
(Synapse dataset syn3242754). Significance of associations were tested by one-way ANOVA
for patient age, purity, and immune infiltration.

Research reproducibility
All results are reproducible using R/Bioconductor(24) and knitr(25) with LaTeX output at
overleaf.com/read/srvqbpxpqbyz. Output of this code is provided as Supplemental File 1.
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Subtyping algorithms are provided by the open source consensusOV R package available from
Bioconductor (http://bioconductor.org/packages/consensusOV).

Results
We performed a meta-analysis of three published subtyping algorithms for HGSOC(5,6,9) and
developed a new consensus classifier to identify unambiguously classifiable tumors (Table 1).
Each of these algorithms identified four distinct HGSOC subtypes with specific clinical and
tumor pathology characteristics (Figure 1). We assessed the algorithms on a compendium of 15
datasets including over 1,700 HGSOC patients (Table 2) with respect to concordance,
robustness, and association to patient outcome. By modifying individual algorithms to discard
tumors of intermediate subtype, we found that concordance between algorithms is greatly
improved.

Concordance of published classifiers
We reimplemented three published HGSOC subtype classifiers(5,6,9) (Table 1) and applied
these methods to new datasets. We ensured correct implementation of classifiers by
reproducing results from the original papers (Supplementary Information). When applied to
independent datasets, pairwise concordance of the three methods was statistically significant (p
< 10-5, Chi-square test; Figure 2A) with the highest agreement observed for Helland and
Konecny subtyping schemes (70.9%), followed by Verhaak and Helland (67.4%) and Verhaak
and Konecny (58.9%). Cramer’s V coefficients(26) indicated a strong association between
subtypes as identified by the different algorithms (>0.5).

Tumors of intermediate subtype
The individual subtyping algorithms calculate numeric scores for each subtype, and assign each
tumor to the subtype with the highest score. A tumor with a large difference or “margin” between
10

the highest and second highest scores can be considered distinctly classifiable, whereas a
tumor with two nearly equal scores could be considered of intermediate subtype. We examined
the effect of modifying the individual algorithms to prevent assignment of indeterminate cases at
various thresholds. For each pair of subtype classifiers, we examined the classification
concordance with increasing thresholds on the margins.

For all pairs of subtype classifier, classification concordance increased as additional marginal
cases are removed, approaching over 90% concordance once the majority of tumors are left
unclassified (Figure 2B). Three-way concordance followed the same trend with lower overall
concordance: a minimum of 23% for the proliferative subtype and maximum of 45% for the
immunoreactive subtype when all tumors are classified. Restricting the concordance analysis to
the top 50% of tumors by margin value resulted in an increased overlap between 35%
(proliferative) and 65% (immunoreactive). At a strict threshold of where only 10% of tumors are
classified, 88% of tumors overall are concordantly classified by all three published subtyping
algorithms (Figure 2C). This large gain in concordance results from large reductions in both
singleton calls - tumors assigned to one subtype by one algorithm, but not by the other two
algorithms - and in 2-to-1 calls, tumors assigned to one subtype by two algorithms, but not by
the third (Figure 2D). This indicates that tumors distinctly classifiable by a single algorithm are
more likely to be concordantly classified by the other algorithms, and conversely, tumors that
appear ambiguous to one algorithm are less likely to be classified in the same way by the other
algorithms.

Survival Analysis
All proposed subtyping algorithms classified patients into groups that significantly differed in
overall survival (Figure 3A, p < 10-5 for each subtyping algorithm, log-rank test). Comparing lowrisk to high-risk subtypes for each algorithm, the hazard ratios increase from approximately 1.5
11

as marginal cases are removed (Figure 3B), suggesting that marginal cases may contribute to
the intermediate survival profiles between subtypes.

Robustness of the Classifiers
Robust molecular subtyping should be replicable in multiple datasets. We performed de novo
clustering in 15 independent ovarian datasets using the authors’ original gene lists and
clustering methods. We compared these de novo clusters to the labels from our implementation
of the published classifiers to assess robustness using the Prediction Strength (PS) statistic(12).
For PS estimation, we included validation datasets with at least 100 HGSOC tumors. Overall we
observed low robustness for all classifiers, with PS values under 0.6 for the three algorithms
across datasets (Supplementary Figure 2), none meeting the 0.8 threshold typically indicating
robust classes(12,17).

To assess whether low confidence predictions are driving the PS estimation, we re-computed
the robustness of each algorithm set to classify varying fractions of the tumors with the highest
margins. We used the largest dataset available, the TCGA dataset, as the validation set, and
varied margin cutoffs of the Tothill and Konecny classifiers to require them to classify between
25% and 100% of the cases. From 10 random clustering runs, we report the median PS for the
dataset. Clustering was performed on the full TCGA dataset and tumors of low margin values
were removed subsequent to clustering and after the classifier was fully defined, in order to
avoid optimistically biasing the apparent strength of clusters. We observed that the robustness
of each algorithm is substantially improved by preventing them tto classify ambiguous cases.
The Tothill algorithm achieved almost perfect robustness (PS = 0.96) when allowed to leave
75% of cases unclassified (Figure 4).

Consensus Classifier
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To maximize concordance across classifiers, we developed consensusOV, a consensus
subtyping scheme facilitating classification of tumors of well-defined subtypes (Figure 5). This
classifier uses binary gene pairs(20,21) to support application across gene expression
platforms. The consensusOV classifier exhibits overall pairwise concordance of 67 - 78% with
each of the other three algorithms, when classifying all tumors; and 94% concordance with
tumors that are concordantly classified by the other three algorithms (Figure 5A). The margins
of consensusOV are higher for concordantly classified cases than for non-concordantly
classified cases, and this difference in margins is greater than for any of the other three
classifiers (Figure 6A). Accordingly, consensusOV was also most effective in identifying
concordantly classified cases, although it was similar to the Konecny classifier in this respect
(AUC = 0.76, Figure 6B). As expected, differences in survival of subsets identified by
consensusOV are similar to those identified by previous classifiers. The highest risk subtypes
are proliferative (HR=1.44, 95% CI: 1.07−1.94) and mesenchymal (HR=1.97, 95% CI:
1.46−2.67) when removing 75% of indeterminate low-margin tumors, with similar hazard ratios
for the concordant cases (Figure 5B).

Discussion
The existence of four distinct and concordant molecular subtypes of HGSOC has been reported
in several studies of large patient cohorts(4–6,9), but also called into question by another
effort(2) that could not identify subtypes, and by an independent validation effort that reported
only two or three reproducible subtypes(27). Meanwhile, significant effort is being expended to
translate these subtypes to clinical practice, for example to predict response to the angiogenesis
inhibitor bevacizumab in the ICON7 trial(28,29). Our study pursues three major objectives: (1)
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reproduction of published subtype classification algorithms as an open-source resource; (2)
evaluation of the robustness and prognostic value of each proposed subtyping scheme in
independent data; and (3) consolidation of proposed subtyping schemes into a consensus
algorithm.

We find that while the proposed 4-subtype classifications demonstrate significant concordance
and association with patient survival, none are robust to re-training in new datasets. By
modifying any of these algorithms to prevent classification of tumors of ambiguous subtype,
robustness and concordance of subtyping algorithms improve dramatically. We propose a
“consensus” classifier that can identify the most unambiguously classifiable tumors, although a
continuous trade-off exists between classifying more tumors versus having greater confidence
in those classified.

Ambiguity in tumor classification might arise from a heterogeneous admixture of different
subtypes, or from a more homogeneous composition of indeterminate subtype. This distinction
has implications for the therapeutic value of the proposed subtypes. Lohr et al. estimated that
90% of tumors in the TCGA HGSOC dataset are polyclonal(30) , and clonal spread of HGSOC
has been directly inferred from single-nucleus sequencing(31). However, it remains unclear
whether multiple clones in a tumor are consistently classifiable to the same subtype. If a tumor
consists of multiple clones of different subtypes, then a subtype-specific therapy will likely lead
to relapse as other clones survive and continue to grow. If this situation is common, even
unambiguously classifiable tumors might be contaminated by small amounts of another subtype
that could lead to relapse after subtype-specific therapy. This question could not be resolved by
the current datasets, but may eventually be addressed by single-cell RNA sequencing(32) which
is expected to further improve precision HGSOC molecular subtyping.
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Several findings stand out in the validation of published subtyping algorithms. First, although
previous studies reported inconsistent findings on whether subtypes differ by patient survival,
our analysis in independent data showed clear survival differences. The 5-year survival rate for
patients with different subtypes ranged from as low as 20% to as high as 50%. Second,
published algorithms do not meet previously defined standards of robustness in terms of
Prediction Strength, a measure of consistency between subtype classifiers trained in
independent datasets. Finally, the concordance of three algorithms, established independently
by different research groups from different patient cohorts, is only moderate but can be greatly
improved by modifying the original algorithms to allow them to leave ambiguous tumors
unclassified. In their original forms, all-way concordance of the four defined classes occurs in
23% to 45% of tumors. As the individual algorithms are modified so they are allowed to leave
ambiguous cases unclassified, the minority of remaining tumors can be classified with over 90%
concordance between the three algorithms. This is a novel finding of interest, because an
alternate possibility was that classifiers trained on different datasets would suffer low
concordance no matter how they treated uncertain tumors. This finding suggests a subset of
tumors of “pure” subtype; unfortunately, such unambiguous cases account for as few as 25% of
HGSOC tumors. This places important limitations on the potential for clinical application of
HGSOC subtypes. The proposed alternative, consensusOV, identifies the consensus of
published HGSOC subtype classifiers. By training on multiple datasets, using binary (pairwise
greater-than or less-than) relationships between pairs of genes, and using a relatively small
gene set, it is designed to identify robustly classifiable HGSOC tumors across gene expression
platforms and datasets.

Moving forward, general agreement on how molecular subgroups of ovarian cancer are defined
would facilitate the use of expression data in clinical management. (33). The present subgroups
while prognostically important are not yet clinically meaningful. Much like other prognostic
15

factors such as age, ascites, and histology, they do not alter clinical management. However, a
better understanding of the biology underlying the subgroups will provide a more rational
targeted treatment of those patients (perhaps first in trial) such as seen in HRD tumors with
PARP inhibitors. The use of algorithms that can classify the tumor of an individual patient, while
allowing some tumors to remain unclassified, along with assessment of subtype robustness in
independent datasets by Prediction Strength, would move the field closer to this goal.
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TABLES
Citation

Probe / gene filtering
for Clustering

Clustering
Algorithm

Probe / gene
filtering for
classification

Subtype
Classifier

Probes with at least one
sample expressed
above 7.0, and global
variance above 0.5

Consensus kmeans; diagonal
LDA and kNN

Gene ranking by
differentially
expressed genes
between groups

Linear subtype
scores

TCGA/Verhaak(4
,5)

Filter to genes that
correlate above 0.7
between three platforms
to unified estimate; then
take top 1500 genes by
median absolute
deviation (MAD)

Non-negative
Matrix
Factorization

Filter patients by
silhouette width;
correlation-based
feature subset
selection

Single-sample
Gene Set
Enrichment
Analysis

Konecny(6)

Top 2500 probes by
MAD, then keep 1850
unique gene symbols

Non-negative
Matrix
Factorization

Prediction Analysis
of Microarrays with
thresholds
determined by 10fold cross validation

Nearest
Centroid with
Spearman’s
rho

consensusOV

100 Genes provided by
Verhaak(5); convert the
features space into
binary matrix of genepair associations

Random Forest
using
unanimously
classified tumors
across the
methods

100 gene symbols
given in Verhaak(5)

Random
Forest
classifier

Tothill/
Helland(3,9)

Table 1: Subtyping methodology of the algorithms reviewed.
GEO(34)
Accession

Sample Size

Microarray Platform

#
Features

TCGA(4)

464:452:239
(43)

Affymetrix HT HG-U133A

12833

GSE17260(35)

43:43 22 (29)

Agilent-012391 Whole HG Oligo

19596

GSE14764(36)

41:41:13 (30)

Affymetrix HG-U133A

12752

GSE18520(37)

53:53:41 (21)

Affymetrix HG-U133 Plus 2.0

20282

GSE26193(38)

47:47:39 (34)

Affymetrix HG-U133 Plus 2.0

20282
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PMID17290060(
39)

59:59:36 (34)

Affymetrix HG-U133A

12752

GSE51088(40)

85:84:69 (44)

Agilent-012097 Human 1A Microarray (V2) 15299
G4110B

GSE13876(41)

98:98:72 (22)

Operon human v3 ~35K 70-mer two-color 13846
oligonucleotide microarrays

GSE49997(42)

132:122:40
(23)

ABI HG Survey Microarray Version 2

16760

E.MTAB.386(43)

128:128:73
(30)

Illumina humanRef-8 v2.0 beadchip

10572

GSE32062(44)

129:129:60
(40)

Agilent-014850 Whole HG 4x44K G4112F

19596

GSE9891(3)

142:140:72
(29)

Affymetrix HG-U133 Plus 2.0

20282

GSE26712(45)

185:185:129
(39)

Affymetrix HG-U133A Array

12752

GSE20565(46)

89 (0)

Affymetrix HG-U133 Plus 2.0

20282

GSE2109

79 (0)

Affymetrix HG-U133Plus2

20282

Table 2: Compendium of gene expression datasets. 15 whole-transcriptome studies with at
least 40 patients with late stage, high-grade serous histology from the curatedOvarianData
compendium consisting of 1,770 patients. 13 of these datasets provided 1,581 patients with
survival data. Sample size column proves the number of samples : number with survival data :
number deceased (median survival in months).
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FIGURE CAPTIONS
Figure 1: Properties of Subtypes identified by Consensus Classifier. Subtype associations
with patient age and overall survival were assessed across our compendium of microarray
datasets; association with tumor purity and immune cell infiltration was assessed using the
TCGA dataset. Tumor purity was estimated from genotyping data in TCGA; lymphocyte
infiltration was based on pathology estimates from TCGA. Patient age (p < 0.001), overall
survival (p < 0.005), and ABSOLUTE purity (p < 0.001) were statistically significant across
subtypes. When compared to all other groups, the Immunoreactive subtype had elevated
infiltration of lymphocytes (p < 0.05) and neutrophils (p < 0.10). Mean monocyte infiltration was
less than 5% across all subtypes, and was excluded from this analysis. Classification was
performed using default parameters, and mean values of each variable are shown.
Figure 2: Concordance Analysis. (A) Contingency table showing concordance of subtypes
while comparing the methods pairwise (B) Pairwise concordance between the methods versus
percentage of the dataset with samples of lower subtype margins removed, (C) three-way
overall concordance between the methods and that of the individual subtypes versus
percentage removed, (D) The classification of patients by three published algorithms as a Venn
diagram for each of the four subtypes. Each area shows percentages of patients when all
patients are classified (below, in parentheses) and after refusing to classify 75% of the most
marginally classified tumors by any of the three methods (above). Thus, the numbers on the top
of the three-way intersection are the concordant tumors according to the three original
algorithms. Bottom numbers indicate relatively unambiguous subtype predictions by all three
algorithms and which are also concordant with the others.
Figure 3: Survival Analysis. (A) Kaplan-Meier curves of subtypes of the 1581 patients with
survival data under different methods. (B) Hazard ratios and 95% confidence intervals of the
lowest-risk subtype (Konecny and Verhaak) or two subtypes (Helland) compared to the
remaining subtypes.
Figure 4: Robustness Analysis of published classifiers, by Prediction Strength. In each
dataset, concordance was calculated between the published classifier and a classifier re-trained
on the validation dataset. The TCGA dataset also classified using the published classifiers of
Helland and Konecny (no re-training was done for the classifiers). The TCGA dataset was also
clustered using the methods of Tothill and Konency (in red and blue respectively). Samples
were removed from Prediction Strength calculations starting with the most ambiguous samples
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(with the smallest difference between the top subtype prediction and runner-up subtype
prediction); the x-axis shows the percent removed before computing prediction strength. Each
algorithm improves in robustness when allowed to leave ambiguous samples, that it is less
certain in its classification, unclassified.
Figure 5: Concordance and Survival Stratification of consensusOV. (A) Contingency plots
showing concordance of subtype classification between consensusOV and the classifiers of
Helland, Verhaak, Konecny. The fourth (bottom-right) plot shows the concordance between the
consensus classifier and the patients concordantly classified between the three classifiers. (B)
Survival curves for the pooled dataset provided by consensusOV. Classification was performed
using leave-one-dataset-out validation. For the bottom two figures, classification with
consensusOV was performed with the default cutoff, in which 75% of patients with the lowest
margin are not classified.
Figure 6: Margin Analysis. (A) Boxplots indicating the margin values assigned by each
classifier to concordant and discordant cases. All statistical tests were performed using the
Wilcoxon rank-sum test. (B) ROC curve for assessing the ability of margin values to discriminate
between concordant and discordant cases.
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